{"title":"COVID-19 的门诊管理：皮肤科医生入门指南》。","authors":"Sonia Wang, Joel M Gelfand, Cassandra Calabrese","doi":"10.1007/s13671-022-00368-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>To summarize diagnostic and therapeutic management of COVID-19 in the outpatient setting for dermatologists.</p><p><strong>Recent findings: </strong>Paxlovid (nirmatrelvir-ritonavir) is the preferred treatment in patients with mild symptoms at high risk of progression to severe SARS-CoV2 infection. Additional options include monoclonal antibodies (bebtelovimab), remdesivir, and molnupiravir.</p><p><strong>Summary: </strong>Dermatologists need to be aware of recent developments in diagnostic and therapeutic management of COVID-19 in the outpatient setting, as their patients may rely on dermatologists to provide advice, particularly in cases where treatments for dermatological disease may impact the risk of COVID-19 and/or vaccine efficacy.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13671-022-00368-3.</p>","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391204/pdf/","citationCount":"0","resultStr":"{\"title\":\"Outpatient Management of COVID-19: A Primer for the Dermatologist.\",\"authors\":\"Sonia Wang, Joel M Gelfand, Cassandra Calabrese\",\"doi\":\"10.1007/s13671-022-00368-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>To summarize diagnostic and therapeutic management of COVID-19 in the outpatient setting for dermatologists.</p><p><strong>Recent findings: </strong>Paxlovid (nirmatrelvir-ritonavir) is the preferred treatment in patients with mild symptoms at high risk of progression to severe SARS-CoV2 infection. Additional options include monoclonal antibodies (bebtelovimab), remdesivir, and molnupiravir.</p><p><strong>Summary: </strong>Dermatologists need to be aware of recent developments in diagnostic and therapeutic management of COVID-19 in the outpatient setting, as their patients may rely on dermatologists to provide advice, particularly in cases where treatments for dermatological disease may impact the risk of COVID-19 and/or vaccine efficacy.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13671-022-00368-3.</p>\",\"PeriodicalId\":10838,\"journal\":{\"name\":\"Current Dermatology Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391204/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13671-022-00368-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/8/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13671-022-00368-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Outpatient Management of COVID-19: A Primer for the Dermatologist.
Purpose of review: To summarize diagnostic and therapeutic management of COVID-19 in the outpatient setting for dermatologists.
Recent findings: Paxlovid (nirmatrelvir-ritonavir) is the preferred treatment in patients with mild symptoms at high risk of progression to severe SARS-CoV2 infection. Additional options include monoclonal antibodies (bebtelovimab), remdesivir, and molnupiravir.
Summary: Dermatologists need to be aware of recent developments in diagnostic and therapeutic management of COVID-19 in the outpatient setting, as their patients may rely on dermatologists to provide advice, particularly in cases where treatments for dermatological disease may impact the risk of COVID-19 and/or vaccine efficacy.
Supplementary information: The online version contains supplementary material available at 10.1007/s13671-022-00368-3.
期刊介绍：
This journal intends to review the most significant recent developments in the field of dermatology. By providing clear, insightful, balanced contributions by expert international authors, the journal aims to serve all those involved in the diagnosis, treatment, management, and prevention of dermatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field, such as epidemiology, surgery, pharmacology, clinical trial design, and pediatrics. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known figures in the field, and an Editorial Board of more than 20 internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
